The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.


Significantly more patients clear or almost clear vs placebo1,a,b

aPost-hoc analysis of pooled patient data from the phase 3 ESTEEM 1 and 2 studies and the phase 2 PSOR-005 study. Among patients with moderate to severe palmoplantar psoriasis at baseline (PPPGA score ≥3; 10.1% [n = 144/1,431]).

bP = 0.021.

OTEZLA cleared or almost cleared psoriasis on the palms and soles1

See the OTEZLA difference

Real patients, real pictures*


Week 16 PASI-70 result

Individual results may vary.

*Photos taken from the ESTEEM clinical trial program, which evaluated OTEZLA 30 mg BID in patients with active plaque psoriasis.

 BID, twice daily; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PPPGA, Palmoplantar Psoriasis Physician Global Assessment.


  1. Bissonnette R, Pariser DM, Wasel NR, et al. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2016;75(1):99-105.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 51 Countries
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Singapore

  • Kuwait

  • Taiwan

  • UAE

  • Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil